dexmedetomidine has been researched along with Disease Models, Animal in 190 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (4.74) | 29.6817 |
| 2010's | 113 (59.47) | 24.3611 |
| 2020's | 68 (35.79) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, WC; He, HF; Li, W; Lin, YL; Liu, WF; Liu, YB; Xu, CJ | 1 |
| Chen, C; Guo, B; Yang, L; Zhu, R | 1 |
| Gao, J; Hu, W; Huang, T; Li, Y; Wang, Z; Xu, Y; Yang, F; Yu, D; Zong, L | 1 |
| Cheng, G; Li, Y; Qiu, G; Wang, Y; Wu, W; Wu, Y; Zhang, H; Zhu, L | 1 |
| Hu, G; Shao, W; Shi, Z; Xu, B | 1 |
| Fang, M; Hu, H; Liang, Z; Sun, H; Tao, T; Xu, X | 1 |
| Cakir-Aktas, C; Karakaya, D; Mut, M; Soylemezoglu, F; Uzun, S | 1 |
| Cai, J; Huang, D; Lin, Y; Lu, J; Luo, Z; Yu, S; Zhou, B | 1 |
| Antunes, MA; Battaglini, D; Cruz, FF; da Silva, CM; Fernandes, MV; Pelosi, P; Robba, C; Rocco, PRM; Samary, CS; Silva, PL; Sousa, GC; Takyia, C | 1 |
| Liu, Y; Qu, X; Wang, J; Wang, X; Zhang, J | 1 |
| Brandt, J; Eckardt, L; Ellermann, C; Frommeyer, G; Lange, PS; Leitz, P; Reinke, F; Wegner, FK; Willy, K; Wolfes, J | 1 |
| Dong, H; Yang, FY; Zhang, L; Zheng, Y | 1 |
| Katoh, T; Kien, TS; Kobayashi, A; Kobayashi, K; Mimuro, S; Nakajima, Y; Sato, T | 1 |
| Hu, M; Ma, T; Xie, H; Xie, Q; Zhang, Q; Zhou, L | 1 |
| Fan, Y; Hu, R; Liao, XZ; Liu, YF; Xiao, JF; Zhang, LF | 1 |
| Chen, L; Dong, S; Duan, F; Hu, M; Huang, J; Men, Y; Zhang, Y | 1 |
| Chen, Y; Cui, J; Li, Y; Mei, Y; Mu, Y; Yu, L; Zhu, D | 1 |
| Amorim, E; Ichinose, F; Ikeda, T; Kato, R; Malhotra, R; Marutani, E; Miyazaki, Y; Silverman, MG; Solt, K | 1 |
| Chen, Y; Cheng, O; Cui, J; Li, C; Li, Y; Zhu, D | 1 |
| Chen, C; Chen, W; Fan, P; Huang, Y; Jin, S; Qi, Z; Qian, L; Zhang, N | 1 |
| Xu, H; Xu, Y; Ye, X | 1 |
| Chen, ZR; Hong, Y; Huang, WQ; Wen, SH; Zhan, YQ | 1 |
| Pupikina, M; Rutskova, E; Sitnikova, E | 1 |
| Li, L; Wang, F; Yao, L; Zhang, Z | 1 |
| Chai, M; Han, M; Li, DB; Liu, YR; Wang, G; Yang, HT; Zhang, XP | 1 |
| Gao, M; Liu, D; Liu, Y; Song, F; Yang, P; Yu, T; Zhang, M; Zhang, X | 1 |
| Beattie, MS; Bresnahan, JC; Chang, YW; Du, Q; Gao, J; Lin, A; Maze, M; Niu, X; Pan, JZ; Sun, W; Sun, Y; Sun, Z; Wang, G; Xiao, Z | 1 |
| Behmenburg, F; Bunte, S; Heinen, A; Hollmann, MW; Huhn, R; Majewski, N; Mathes, A; Raupach, A; Stroethoff, M | 1 |
| Dai, D; Han, H; Hu, J; Lu, L; Tao, G; Zhang, R; Zhu, J | 1 |
| Liu, H; Pang, X; Zhang, P; Zhao, J; Zhou, Y | 1 |
| Chen, WR; Ji, FH; Liu, H; Liu, HY; Meng, XW; Peng, K; Xia, F; Xia, ZY; Zhang, J | 1 |
| Feng, J; Lan, J; Peng, W; Zheng, J | 1 |
| Baillie, JK; Edwardson, SA; Flanders, CA; Rocke, AS; Walsh, TS | 1 |
| Bo, Z; Fang, Z; Kang, L; Yayi, H; Zhongyuan, X | 1 |
| Doğan, G; Karaca, O | 1 |
| Bian, W; Chen, Y; Xu, B | 1 |
| Chen, J; Qiu, J; Wang, R; Xie, Y | 1 |
| Guo, F; Jia, L; Kang, J; Tan, J; Wang, Y; Xu, H | 1 |
| Chen, J; Chen, T; Chi, X; Deng, Y; Liu, P; Tan, F; Tian, J; Zheng, L | 1 |
| Chen, H; Cheng, L; Jiang, L; Li, P; Tan, X; Tu, S; Tu, Z; Zeng, Y | 1 |
| Li, Y; Ma, W; Ren, X; Wang, Y; Yang, K; Zhang, X; Zhong, M; Zhuang, Y | 1 |
| Chen, P; Dai, G; Hong, J; Jiang, Y; Li, A; Lin, W; Luo, X; Luo, Y; Ning, X; Peng, S; Qu, C; Wang, H; Xie, P | 1 |
| Coopersmith, CM; Paterson, CW | 1 |
| Gao, H; Hu, BL; Li, YP; Yin, YQ; Zhong, Y | 1 |
| Huang, Q; Kong, Q; Ming, T; Wu, X; Xia, Z; Yuan, M | 1 |
| Arslan, M; Aşçı, SS; Erdem, Ö; Kartal, S; Kavutçu, M; Kip, G; Küçük, A | 1 |
| Bealer, SL; Dudek, FE; Smolik, M; Spampanato, J | 1 |
| Jin, X; Li, Z; Pan, D; Shen, R; Wang, H; Wang, Z | 1 |
| Akça, B; Ankay Yılbaş, A; Bahador Zırh, E; Büyükakkuş, B; Sarıcaoğlu, F; Üzümcügil, F; Zeybek, D | 1 |
| Fan, J; Han, X; Leng, Y; Liu, Y; Ma, X; Xue, X; Yu, J | 1 |
| Du, J; Gu, M; Li, C; Li, S; Li, W; Liu, H; Sun, Q; Weng, X; Xu, Y; Zhang, X | 1 |
| Wu, Z; Xue, H; Zhang, Y; Zhao, P | 1 |
| An, M; Deni, W; Hou, L; Jin, K; Ta Na, HS; Zhang, T | 1 |
| Li, H; Lu, C; Xu, L; Yao, W; Zheng, B; Zhou, J | 1 |
| Nie, Y; Shan, SQ; Wang, BQ; Wang, L; Yu, J; Zhu, CH | 1 |
| Cui, E; Li, M; Sun, J; Yan, M; Zhang, H; Zhang, Y; Zhou, J; Zhu, X | 1 |
| Dong, Y; Li, M; Liang, F; Soriano, SG; Sun, M; Xie, Z; Zhang, J; Zhang, Y | 1 |
| He, L; Qian, J; Song, N; Wang, Z; Xiong, W; Yang, Y; Zhou, R | 1 |
| Li, GC; Li, ZB; Qin, J | 1 |
| Cai, X; Huang, W; Li, Y; Wang, Q; Wang, Z; Ye, F; Zheng, X; Zuo, Z | 1 |
| Fang, H; Li, HF; Yan, JY; Yang, M; Zhang, JP | 1 |
| Cai, J; Chen, S; Ju, Y; Lu, J; Xiao, F; Zhou, B | 1 |
| Chen, J; Chen, W; Cheng, Q; Li, Y; Lv, H | 1 |
| Araújo, RLTM; Barbosa Neto, JO; Cartagenes, MDSS; Czeczko, NG; Garcia, JBS; Gomes, LMRS | 1 |
| Cai, L; Deng, Y; Huang, J; Li, L; Lv, H; Wang, F; Wang, H | 1 |
| Hou, X; Kong, M; Ni, H; Shao, Z; Shen, Q | 1 |
| Hao, FG; Huang, GR | 1 |
| Dai, M; Deng, J; Hu, R; Li, Q; Liu, Q; Yang, X; Yu, Q; Zhao, Y | 1 |
| Cheng, D; Li, H; Li, Y; Qu, M; Xing, F; Xing, N; Zhang, W | 1 |
| Yuki, K | 1 |
| Liu, Y; Ma, X; Zhang, W; Zhao, H; Zhu, Y | 1 |
| Fan, D; Gu, P; Li, G | 1 |
| Dong, H; Jiang, J; Jiao, Y; Shao, J; Tang, D; Wang, Z; Xu, S; Yin, W; Yu, W; Zhang, Y; Zhou, W | 1 |
| Feng, X; Jiao, W; Ma, W; Wang, Y; Zhu, J | 1 |
| Liu, W; Shao, C; Sun, J; Wang, Y; Xu, M; Zang, C | 1 |
| Abrial, E; Arnt, J; Delcourte, S; Didriksen, M; Etiévant, A; Haddjeri, N; Rovera, R | 1 |
| Berardi, A; Campolongo, P; Morena, M; Palmery, M; Peloso, A; Schelling, G; Trezza, V; Valeri, D | 1 |
| Chen, H; Jiang, K; Wang, J; Wu, JR; Yao, YY; Zhang, DX; Zhang, MM; Zhou, B | 1 |
| Chen, H; Cheng, X; He, X; Yan, X; Zheng, W; Zhou, L | 1 |
| Andropoulos, DB | 1 |
| Bai, X; Chen, X; Huang, J; Huang, Z; Nie, B; Ouyang, H; Zeng, W; Zhang, S; Zheng, Y | 1 |
| Ewing, L; Hofacer, RD; Joseph, B; Lee, JR; Lee, SY; Lin, EP; Loepke, AW; Upton, B | 1 |
| Brambrink, AM; Grafe, MR; Perez-Zoghbi, JF; Zhu, W | 1 |
| Sunada, K; Tsutsui, Y | 1 |
| Chen, J; Li, H; Li, N; Lim, G; Ma, W; McCabe, MF; Yang, Y; Zhao, W | 1 |
| Çelik, F; Doğan, E; Güzel, A; Kaplan, İ; Kuyumcu, M; Türkçü, G; Yıldırım, ZB | 1 |
| Pang, Q; Wang, Z; Zhou, W; Zhou, X; Zhou, Y | 1 |
| Dong, Z; Li, C; Liu, H; Liu, Y; Ren, J | 1 |
| Arbutus, JA; Ardinger, C; Dunn, EN; Jackson, CE; McCarren, HS; McDonough, JH | 1 |
| Cheng, CC; Jeong, W; Jung, MJ; Kim, DS; Kung, H; Lee, J; Lim, C; Shin, Y | 1 |
| Bozkurt, G; Erbay, FK; Ergül, G; Güvenç, Y; Kırçıl, C; Öztürk, Y; Şentürk, S; Tolunay, T; Yaman, ME | 1 |
| Chen, J; Gao, X; Kulwin, C; Lin, B; Vogel, T; Wu, J | 1 |
| Cheng, Z; Feng, J; Li, A; Qian, H; Wu, Y; Xiao, H; Yan, F; Yang, Q; Zhang, X; Zhao, Z | 1 |
| Abd-Ellatief, RB; Kotb, HI; Mohamed, HK | 1 |
| Elgendy, H; Elmorsy, SA; Rashed, LA; Soliman, GF | 1 |
| Cheng, J; Li, X; Peng, X; Qin, H; Yu, H; Zhu, P | 1 |
| Gao, Y; Huang, R; Kang, K; Kong, WL; Liu, HT; Liu, RJ; Liu, YS; Qi, ZD; Qu, JD; Wang, HL; Wang, SC; Yu, KJ; Zhang, X; Zheng, JB | 1 |
| Hu, PS; Liu, J; Meng, PZ; Tong, F | 1 |
| Bevan, C; Date, A; Datoo, T; Jiang, C; Ma, D; Sanders, RD; Wang, C; Wang, G; Wu, L; Zhao, H | 1 |
| Fang, T; Fu, Q; Liu, C; Mu, R; Tian, F; Wang, F; Yu, B; Zhang, L; Zhang, Y; Zhou, C | 1 |
| Ding, M; Li, JY; Ren, HC; Wang, G; Wang, Q; Weng, YQ; Xu, RB; Yu, HL; Yu, WL | 1 |
| Guo, X; Li, H; Ruan, X; Xu, L; Ying, Y; Zhang, S; Zheng, B | 1 |
| Chen, Y; Fan, H; Feng, X; Hu, X; Li, B; Sha, J; Zhang, H | 2 |
| Doi, M; Katoh, T; Kawashima, S; Kobayashi, A; Kobayashi, K; Makino, H; Mimuro, S; Nakajima, Y; Sato, T | 1 |
| Bennett, RC; Kallio-Kujala, IJ; Meierjohann, A; Raekallio, MR; Savontaus, E; Scheinin, M; Spillmann, T; Vainio, OM; Yatkin, E | 1 |
| Fan, H; Feng, X; Hu, X; Sha, J; Song, M; Wang, C; Zhang, H; Zhao, Y | 1 |
| Liang, S; Liu, Y; Wang, Y | 1 |
| Alam, A; Cui, J; Ma, D; Mu, DL; Sun, YB; Wang, DX; Wu, L; Zhang, W; Zhao, H | 1 |
| Huang, J; Jiang, Q | 1 |
| Ding, D; Huang, Q; Jiang, Y; Li, Y; Xia, M; Zhang, X; Zhang, Z | 1 |
| Chen, H; Cheng, L; Han, W; Jiang, L; Li, P; Liu, W; Song, X; Tan, X; Tu, S; Tu, Z | 1 |
| Du, J; Leng, JY; Liu, J; Xu, Z; Yang, D; Zhen, J; Zheng, EL | 1 |
| Aidoni, Z; Dardalas, I; Grosomanidis, V; Kouvelas, D; Malliou, F; Milonas, A; Papazisis, G; Pourzitaki, C; Rigopoulos, P; Stamoula, E; Tsaousi, G | 1 |
| Cao, D; Cao, J; Chen, L; Cong, H; Wang, M; Xiang, H; Yang, Y; Ying, T | 1 |
| Fang, H; He, MH; Li, HF; Wang, QY; Wang, RR; Yan, JY; Yang, M; Zhang, FX; Zhang, JP | 1 |
| Chen, H; Jiang, XQ; Jin, YH; Li, ZT; Wu, F; Zhang, YY | 1 |
| Wang, M; Wang, N | 1 |
| Jiang, H; Liu, DH; Wang, GN; Zhang, J | 1 |
| Bi, L; Jia, Z; Li, XK; Yang, SC | 1 |
| Akkuş, M; Altekin, E; Cilaker Mıcılı, S; Duru, S; Ergür, BU; Girgin, P; Gündüz, K; Güzeldağ, S; Koca, U; Olguner, ÇG; Taşdöğen, A | 1 |
| Celik, F; Evliyaoğlu, O; Fırat, U; Göçmez, C; Guzel, A; Kamaşak, K; Tokgoz, O; Tufek, A | 1 |
| Durmus, M; Erdogan Kayhan, G; Ersoy, MÖ; Gedik, E; Gul, M; Kayhan, B; Kurtoglu, EL; Ozgul, U | 1 |
| Agoston, VA; Bell, MT; Freeman, KA; Fullerton, DA; Herson, PS; Mares, J; Puskas, F; Reece, TB | 1 |
| Bell, MT; Bennett, DT; Fullerton, DA; Herson, PS; Puskas, F; Quillinan, N; Reece, TB | 1 |
| Dogan, Z; Elbe, H; Gul, M; Kayhan, B; Otlu, A | 1 |
| Choi, JI; Kim, YO; Lee, HG; Yoon, MH | 1 |
| Chen, C; Chen, K; Peng, M; Wang, Y; Zhang, F; Zhang, Z | 1 |
| Anderson, B; Broad, K; Ezzati, M; Faulkner, S; Fierens, I; Fleiss, B; Gressens, P; Hassell, J; Kawano, G; Maze, M; Robertson, NJ; Rostami, J; Sanders, RD; Sleigh, JW | 1 |
| Chen, ZY; Liu, ZX; Miao, B; Wu, JR; Zhou, TT | 1 |
| Ji, MH; Jia, M; Liu, WX; Wang, ZY; Xie, ZC; Yang, JJ; Zhang, MQ | 1 |
| Dong, Z; Duan, X; Huang, L; Li, Y; Zhou, C | 1 |
| Araújo, MN; Cavalcanti, V; Fernandes, FC; Heil, LB; Morales, MM; Pelosi, P; Rocco, PR; Samary, CS; Santos, CL; Silva, PL; Villela, N | 1 |
| Alkan, M; Arslan, M; Comu, FM; Kip, G; Kiraz, HA; Ozer, A; Sivgin, V | 1 |
| Dong, J; Tang, J; Yang, L; Zheng, J | 1 |
| Cao, YY; Ding, XD; Zhao, GY; Zhao, P; Zheng, NN | 1 |
| Braz, JR; Braz, LG; Castiglia, YM; de Carvalho, AL; Domingues, MA; Kakuda, CM; Módolo, MP; Módolo, NS; Ribeiro, OR; Vital, RB | 1 |
| Bendix, I; Bührer, C; Endesfelder, S; Krain, M; Paeschke, N; Sifringer, M; Spies, CD; von Haefen, C | 1 |
| Cakir, M; Polat, A; Rumeysa Duran, Z; Tanbek, K; Taslidere, E; Tekin, S; Vardi, N | 1 |
| Bekker, A; Eloy, JD; Li, J; Nadavaluru, PR; Xiong, M; Ye, JH; Zuo, W | 1 |
| Bi, B; Fang, B; Li, XQ; Liu, G; Ma, H; Tan, WF; Zhang, Y | 1 |
| Adesina, A; Akinkuotu, AC; Lazar, DA; Olutoye, OA; Olutoye, OO | 1 |
| Gao, X; Gu, SL; Han, JP; Hu, B; Li, M; Ma, TF; Ma, X; Qin, SJ; Wu, YQ; Zhou, L | 1 |
| Hai-Chen, C; Ji-Shun, N; Shou-Shi, W; Ting-Ting, S | 1 |
| Li, C; Lv, C; Wang, Y; Xu, Y; Yin, X; Zhang, R; Zhang, X; Zhao, W | 1 |
| Liu, H; Liu, T; Wu, D; Yang, Y; Zhang, Q | 1 |
| Atasoy, P; Bal, F; Batislam, E; Kisa, U; Ozan, T; Tuglu, D; Yilmaz, E; Yuvanc, E | 1 |
| Chen, JH; Jin, SY; Lei, DX; Song, XR; Yu, GF; Zhang, WH; Zhou, SL | 1 |
| de Carvalho, AL; de Pereira Cardoso, HD; de Vasconcelos Machado, VM; Fim, NC; Ganem, EM; Lima, RM; Marques, MA; Mint, H; Navarro, LH; Solanki, DR | 1 |
| Han, R; Wang, Y; Zuo, Z | 1 |
| Abdel-Sater, KA; Farghaly, HS; Mahmoud, AM | 1 |
| Aksoy, N; Aydogan, H; Büyükfirat, E; Karahan, MA; Kocarslan, S; Kücük, A; Taskın, A; Yalcin, S; Yüce, HH | 1 |
| Ji, FH; Meng, XW; Peng, K; Zhu, YJ | 1 |
| Cheng, XY; Gao, Q; Gu, XY; Li, XH; Zhang, Y; Zong, QF | 1 |
| Guo, X; Han, B; Mao, M; Wang, J; Wang, Y; Wu, C; Xu, F | 1 |
| Bao, HG; Chen, LH; Han, L; Pan, XX; Si, YN; Sun, F; Xu, YJ; Zeng, LQ; Zhang, Y | 1 |
| Chen, Q; Gu, J; Lu, K; Ma, D; Ma, J; Ning, J; Wu, L; Yi, B | 1 |
| Alizadeh, L; Arhami-Dolatabadi, A; Daneshbod, Y; Hosseinian, MA; Khandaghy, M; Memari, E; Mirabotalebi, M; Mirkheshti, A; Shirian, S | 1 |
| Li, N; Lin, CS; Liu, J; Liu, L; Ouyang, BS; Xing, DD | 1 |
| Cabrera, OH; Dougherty, JD; Farber, NB; Noguchi, KK; O'Connor, SD; Salinas-Contreras, P; Singh, S; Swiney, BS | 1 |
| Chen, SB; Hou, BC; Huang, J; Liu, WC; Luo, XL; Wang, XF; Zhan, YP | 1 |
| Jiang, L; Li, ZJ; Ran, K; Wang, D; Zhang, SB; Zhang, Y | 1 |
| Akpınar, H; Akpınar, O; Nazıroğlu, M | 1 |
| Han, F; Liu, Z; Ning, Q; Sun, H; Wang, X; Yang, M; Zhang, J; Zhang, R; Zhang, X; Zhao, W | 1 |
| Hamilton, C; Ma, Y; Zhang, N | 1 |
| Buyukbas, S; Cosar, M; Eser, O; Fidan, H; Mollaoglu, H; Sahin, O; Songur, A; Yaman, M | 1 |
| Inaba, H; Kobayashi, K; Kurita, A; Taniguchi, T; Yamamoto, K | 1 |
| Christianson, CA; Hua, XY; Nazarian, A; Yaksh, TL | 1 |
| Huang, CJ; Tsai, PS; Yang, CL | 1 |
| Altunbaş, K; Aslan, A; Baş, O; Buyukokuroglu, ME; Cemek, M; Cosar, M; Ela, Y; Eser, O; Fidan, H | 1 |
| Slosberg, PS | 1 |
| Acikgoz, B; Ayoglu, H; Bahadir, B; Bektas, S; Gul, S; Hanci, V; Mungan, AG; Turan, IO | 1 |
| Chen, CH; Huang, CJ; Tsai, PS; Wang, TY; Yang, CL | 1 |
| Deng, XM; Lû, N; Xu, B; Xu, H; Yang, JL; Zhang, WS; Zhang, YQ | 1 |
| Albayrak, Y; Dursun, H; Halici, Z; Odabasoglu, F; Polat, B; Suleyman, B; Suleyman, H; Yigiter, M | 1 |
| Cao, M; Fu, Y; He, H; Ji, F; Liang, J; Liu, L | 1 |
| Cui, S; Gu, X; Liu, Y; Ma, Z; Zhang, J; Zhang, W; Zheng, Y | 1 |
| Hanci, V; Sipahi, EY; Turan, IÖ; Yurdakan, G; Yurtlu, S | 1 |
| Coburn, M; Eberhardt, G; Fahlenkamp, AV; Loetscher, PD; Rex, S; Rossaint, R; Schoeler, M; Weis, J | 1 |
| Chan, WS; Fan, SZ; Ko, WJ; Lin, TY; Sun, WZ; Tsai, JC; Yeh, YC | 1 |
| Citil, M; Hanci, V; Kiliç, K; Kiliç, N; Selek, S; Sözmen, M; Yurtlu, BS; Yurtlu, DA | 1 |
| Applegate, R; Benggon, M; Chen, H; Martin, R; Zhang, JH | 1 |
| Aydogan, MS; Durmus, M; Erdogan, MA; Kurt, A; Parlakpinar, H; Ucar, M; Yucel, A | 1 |
| Ajiki, K; Hayami, N; Kanamori, K; Kunishima, T; Mikamo, T; Murakawa, Y; Sugiura, A; Tsutsui, K; Watanabe, H; Yamagishi, N; Yamagishi, S | 1 |
| Alver, A; Cekic, B; Ertürk, E; Geze, S; Imamoğlu, M; Mentese, A; Tusat, M; Yörük, MF; Yuluğ, E | 1 |
| Choi, JH; Kang, SH; Kim, YH; Koh, HJ; Moon, DE; Park, CS; Park, HJ | 1 |
| Li, N; Meng, Q; Song, X; Wu, X; Xia, Z; Zhan, L | 1 |
| Hall, SR; Hong, M; Milne, B; Wang, L | 1 |
| Kurita, T; Mochizuki, T; Morita, K; Okada, H; Sato, S | 1 |
| Bousquet, P; Feldman, J; Fellmann, L | 1 |
4 review(s) available for dexmedetomidine and Disease Models, Animal
| Article | Year |
|---|---|
The effect of dexmedetomidine and clonidine on the inflammatory response in critical illness: a systematic review of animal and human studies.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Clonidine; Critical Illness; Dexmedetomidine; Disease Models, Animal; Humans; Inflammation | 2019 |
The immunomodulatory mechanism of dexmedetomidine.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Humans; Immunologic Factors; Inflammation Mediators; Leukocytes; Perioperative Period; Receptors, Adrenergic, alpha-2; Stress, Physiological; Surgical Procedures, Operative | 2021 |
Effect of Anesthesia on the Developing Brain: Infant and Fetus.
Topics: Age Factors; Anesthesia; Anesthetics; Animals; Apoptosis; Behavior, Animal; Brain; Child; Child Behavior; Child Development; Child, Preschool; Dexmedetomidine; Disease Models, Animal; Gestational Age; Humans; Infant; Infant Behavior; Neurogenesis; Neurons; Neuroprotective Agents; Neurotoxicity Syndromes | 2018 |
Dexmedetomidine effects in different experimental sepsis in vivo models.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Humans; Organ Specificity; Sepsis | 2019 |
1 trial(s) available for dexmedetomidine and Disease Models, Animal
| Article | Year |
|---|---|
Effects of dexmedetomidine and MK-467 on plasma glucose, insulin and glucagon in a glibenclamide-induced canine hypoglycaemia model.
Topics: Adrenergic alpha-2 Receptor Agonists; Anesthesia, Intravenous; Animals; Blood Glucose; Cross-Over Studies; Dexmedetomidine; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucagon; Glyburide; Hypnotics and Sedatives; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Quinolizines; Random Allocation; Treatment Outcome | 2018 |
185 other study(ies) available for dexmedetomidine and Disease Models, Animal
| Article | Year |
|---|---|
Dexmedetomidine alleviates traumatic spinal cord injury in rats via inhibiting apoptosis induced by endoplasmic reticulum stress.
Topics: Animals; Apoptosis; Dexmedetomidine; Disease Models, Animal; Endoplasmic Reticulum Stress; Male; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries | 2022 |
Effects of dexmedetomidine on postoperative cognitive function of sleep deprivation rats based on changes in inflammatory response.
Topics: Animals; Cognition; Dexmedetomidine; Disease Models, Animal; Gene Expression Regulation; Hippocampus; Injections, Intraperitoneal; Interleukin-1beta; Interleukin-6; Male; Malondialdehyde; Morris Water Maze Test; Neuropeptides; NF-kappa B; Oxidative Stress; Postoperative Complications; Proto-Oncogene Proteins c-akt; rac1 GTP-Binding Protein; Random Allocation; Rats; Rats, Sprague-Dawley; Sleep Deprivation; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2021 |
Dexmedetomidine attenuates haemorrhage-induced thalamic pain by inhibiting the TLR4/NF-κB/ERK1/2 pathway in mice.
Topics: Analgesics, Non-Narcotic; Animals; Dexmedetomidine; Disease Models, Animal; Hemorrhage; Inflammation; Male; MAP Kinase Signaling System; Mice; Neuralgia; NF-kappa B; Signal Transduction; Toll-Like Receptor 4 | 2021 |
Dexmedetomidine alleviates hepatic ischaemia-reperfusion injury via the PI3K/AKT/Nrf2-NLRP3 pathway.
Topics: Animals; Biomarkers; Dexmedetomidine; Disease Models, Animal; Gene Expression Regulation; Liver Diseases; NF-E2-Related Factor 2; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphatidylinositol 3-Kinases; Protective Agents; Proto-Oncogene Proteins c-akt; Rats; Reperfusion Injury; Signal Transduction | 2021 |
MicroRNA-214-5p involves in the protection effect of Dexmedetomidine against neurological injury in Alzheimer's disease via targeting the suppressor of zest 12.
Topics: Alzheimer Disease; Animals; Dexmedetomidine; Disease Models, Animal; Hippocampus; Mice; MicroRNAs; Neuroprotective Agents; Polycomb Repressive Complex 2 | 2022 |
Protective effect of dexmedetomidine in cecal ligation perforation-induced acute lung injury through HMGB1/RAGE pathway regulation and pyroptosis activation.
Topics: Acute Lung Injury; Animals; Cecum; Cell Line; Cell Nucleus; Cytokines; Dexmedetomidine; Disease Models, Animal; HMGB1 Protein; Inflammation Mediators; Lentivirus; Ligation; Lung; Male; Mice, Inbred C57BL; Protective Agents; Protein Transport; Pyroptosis; Receptor for Advanced Glycation End Products; RNA, Messenger; Signal Transduction | 2021 |
Tailored Therapeutic Doses of Dexmedetomidine in Evolving Neuroinflammation after Traumatic Brain Injury.
Topics: Animals; Anti-Inflammatory Agents; Brain Injuries, Traumatic; Dexmedetomidine; Disease Models, Animal; Humans; Interleukin-1beta; Mice; Neuroinflammatory Diseases; NLR Family, Pyrin Domain-Containing 3 Protein | 2022 |
Effects of dexmedetomidine on the expression profile of tsRNAs in LPS-induced acute lung injury.
Topics: Acute Lung Injury; Animals; Dexmedetomidine; Disease Models, Animal; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; RNA, Transfer; Sequence Analysis, RNA; Signal Transduction; Transcriptome | 2022 |
Comparative effects of dexmedetomidine and propofol on brain and lung damage in experimental acute ischemic stroke.
Topics: Animals; Brain; Brain Ischemia; Dexmedetomidine; Disease Models, Animal; Endothelial Cells; Hypnotics and Sedatives; Interleukin-1beta; Interleukin-6; Ischemic Stroke; Lung; Macrophages, Alveolar; Male; Propofol; Rats; Rats, Wistar; Thiopental; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2021 |
Effects of dexmedetomidine on the degree of myocardial ischemia-reperfusion injury, oxidative stress and TLR4/NF-κB signaling pathway in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Dexmedetomidine; Disease Models, Animal; Male; Myocardial Reperfusion Injury; Myocytes, Cardiac; NF-kappa B; Oxidative Stress; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptor 4 | 2021 |
Safe electrophysiologic profile of dexmedetomidine in different experimental arrhythmia models.
Topics: Animals; Arrhythmias, Cardiac; Dexmedetomidine; Disease Models, Animal; Electrophysiologic Techniques, Cardiac; Heart Conduction System; Isolated Heart Preparation; Rabbits | 2021 |
Dexmedetomidine attenuates ischemia and reperfusion-induced cardiomyocyte injury through p53 and forkhead box O3a (FOXO3a)/p53-upregulated modulator of apoptosis (PUMA) signaling signaling.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Line; Dexmedetomidine; Disease Models, Animal; Forkhead Box Protein O3; Male; Mice; Mitochondria; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxidative Stress; Rats; Signal Transduction; Tumor Suppressor Protein p53 | 2022 |
Dexmedetomidine suppresses serum syndecan-1 elevation and improves survival in a rat hemorrhagic shock model.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Inflammation; Rats; Rats, Sprague-Dawley; Resuscitation; Shock, Hemorrhagic; Syndecan-1; Tumor Necrosis Factor-alpha | 2022 |
Dexmedetomidine attenuates motor deficits via restoring the function of neurons in the nigrostriatal circuit in Parkinson's disease model mice.
Topics: Animals; Corpus Striatum; Dexmedetomidine; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Humans; Mice; Mice, Inbred C57BL; Parkinson Disease | 2022 |
Effects of dexmedetomidine on cognitive dysfunction and neuroinflammation via the HDAC2/HIF-1α/PFKFB3 axis in a murine model of postoperative cognitive dysfunction.
Topics: Animals; Cognitive Dysfunction; Dexmedetomidine; Disease Models, Animal; Hippocampus; Histone Deacetylase 2; Hypoxia-Inducible Factor 1, alpha Subunit; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Neuroinflammatory Diseases; Phosphofructokinase-2; Postoperative Cognitive Complications | 2022 |
Dexmedetomidine exerts its protective effect on cerebral ischemia reperfusion injury in mice by inhibiting ferroptosis.
Topics: Animals; Brain Ischemia; Dexmedetomidine; Disease Models, Animal; Ferroptosis; Infarction, Middle Cerebral Artery; Ischemic Stroke; Male; Mice; Mice, Inbred ICR; NF-E2-Related Factor 2; Reperfusion Injury | 2022 |
Perisciatic Nerve Dexmedetomidine Alleviates Spinal Oxidative Stress and Improves Peripheral Mitochondrial Dynamic Equilibrium in a Neuropathic Pain Mouse Model in an AMPK-Dependent Manner.
Topics: AMP-Activated Protein Kinases; Animals; Dexmedetomidine; Disease Models, Animal; Membrane Proteins; Mice; Mitochondrial Dynamics; Nerve Tissue Proteins; Neuralgia; Oxidative Stress | 2022 |
Post-cardiac arrest Sedation Promotes Electroencephalographic Slow-wave Activity and Improves Survival in a Mouse Model of Cardiac Arrest.
Topics: Animals; Cardiopulmonary Resuscitation; Dexmedetomidine; Disease Models, Animal; Electroencephalography; Female; Heart Arrest; Hyperemia; Hypothermia; Hypothermia, Induced; Male; Mice; Mice, Inbred C57BL; Propofol | 2022 |
Dexmedetomidine alleviates pain in MPTP-treated mice by activating the AMPK/mTOR/NF-κB pathways in astrocytes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; AMP-Activated Protein Kinases; Animals; Astrocytes; Dexmedetomidine; Disease Models, Animal; Dopaminergic Neurons; Interleukin-6; Mice; Mice, Inbred C57BL; NF-kappa B; Pain; Parkinson Disease; Quality of Life; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2022 |
Dexmedetomidine provides type-specific tumour suppression without tumour-enhancing effects in syngeneic murine models.
Topics: Animals; Breast Neoplasms; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Dexmedetomidine; Disease Models, Animal; Female; Humans; Lung Neoplasms; Mice | 2023 |
Dexmedetomidine alleviates intestinal barrier dysfunction and inflammatory response in mice via suppressing TLR4/MyD88/NF-κB signaling in an experimental model of ulcerative colitis.
Topics: Animals; Colitis; Colitis, Ulcerative; Dexmedetomidine; Disease Models, Animal; Female; Fluorescein-5-isothiocyanate; Intestinal Mucosa; Mice; Mice, Inbred C57BL; Models, Theoretical; Myeloid Differentiation Factor 88; NF-kappa B; Toll-Like Receptor 4 | 2022 |
Dexmedetomidine Pretreatment Protects Against Myocardial Ischemia/Reperfusion Injury by Activating STAT3 Signaling.
Topics: Animals; Apoptosis; Creatine Kinase, MB Form; Dexmedetomidine; Disease Models, Animal; Hypoxia; Mice; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Rats; Receptors, Adrenergic, alpha; Reperfusion Injury; Signal Transduction | 2023 |
Alpha2 Adrenergic Modulation of Spike-Wave Epilepsy: Experimental Study of Pro-Epileptic and Sedative Effects of Dexmedetomidine.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Electroencephalography; Epilepsy, Absence; Female; Hypnotics and Sedatives; Male; Rats; Rats, Wistar | 2023 |
Knock-down of JAK2 and PTEN on pain behavior in rat model of trigeminal neuropathic pain.
Topics: Animals; Dental Implants; Dexamethasone; Dexmedetomidine; Disease Models, Animal; Gene Knockdown Techniques; Hyperalgesia; Janus Kinase 2; Male; Neuralgia; Pain Measurement; PTEN Phosphohydrolase; Rats; Rats, Sprague-Dawley; Trigeminal Neuralgia | 2019 |
High‑fat treatment prevents postoperative cognitive dysfunction in a hyperlipidemia model by protecting the blood‑brain barrier via Mfsd2a‑related signaling.
Topics: Animals; Blood-Brain Barrier; Dexmedetomidine; Diet, High-Fat; Disease Models, Animal; Gene Expression Regulation; Hyperlipidemias; Membrane Transport Proteins; Permeability; Postoperative Cognitive Complications; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction | 2019 |
Dexmedetomidine prevents septic myocardial dysfunction in rats via activation of α7nAChR and PI3K/Akt- mediated autophagy.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Apoptosis; Autophagy; Cell Cycle Checkpoints; Cell Line; Cytokines; Dexmedetomidine; Disease Models, Animal; Heart Diseases; Inflammation Mediators; Male; Myocytes, Cardiac; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Rats, Wistar; Sepsis; Signal Transduction; Ventricular Function, Left | 2019 |
Dexmedetomidine modulates neuroinflammation and improves outcome via alpha2-adrenergic receptor signaling after rat spinal cord injury.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Cells, Cultured; Dexmedetomidine; Disease Models, Animal; Female; Inflammation; Microglia; Rats; Rats, Long-Evans; Receptors, Adrenergic, alpha-2; Signal Transduction; Spinal Cord; Spinal Cord Injuries | 2019 |
Characteristics of Dexmedetomidine Postconditioning in the Field of Myocardial Ischemia-Reperfusion Injury.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Isolated Heart Preparation; Male; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Rats, Wistar; Time Factors; Ventricular Function, Left | 2020 |
Dexmedetomidine improves cardiac function and protects against maladaptive remodeling following myocardial infarction.
Topics: Animals; Apoptosis; Biomarkers; Biopsy; Cardiotonic Agents; Dexmedetomidine; Disease Models, Animal; Fibrosis; Male; Mice; Myocardial Infarction; Oxidative Stress; Superoxide Dismutase; Ventricular Dysfunction, Left; Ventricular Function; Ventricular Remodeling | 2019 |
Dexmedetomidine pretreatment attenuates isoflurane-induced neurotoxicity via inhibiting the TLR2/NF-κB signaling pathway in neonatal rats.
Topics: Anesthetics; Animals; Animals, Newborn; Apoptosis; Dexmedetomidine; Disease Models, Animal; Hippocampus; Humans; Isoflurane; Neurons; Neuroprotective Agents; NF-kappa B; Rats; Signal Transduction; Toll-Like Receptor 2; Transcription Factor RelA | 2020 |
Dexmedetomidine post-treatment attenuates cardiac ischaemia/reperfusion injury by inhibiting apoptosis through HIF-1α signalling.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Apoptosis; Dexmedetomidine; Disease Models, Animal; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Protective Agents; Rats; Rats, Sprague-Dawley | 2020 |
Nrf2 mediates the antinociceptive activity of dexmedetomidine in an acute inflammatory visceral pain rat model by activating the NF-κB sensor.
Topics: Acute Disease; Analgesics; Animals; Dexmedetomidine; Disease Models, Animal; Inflammation; Male; NF-E2-Related Factor 2; NF-kappa B; Nociception; Rats; Rats, Sprague-Dawley; Visceral Pain | 2020 |
Dexmedetomidine attenuates P2X4 and NLRP3 expression in the spine of rats with diabetic neuropathic pain.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blotting, Western; Dexmedetomidine; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Interleukin-1beta; Male; Microscopy, Electron, Transmission; Neural Conduction; NLR Family, Pyrin Domain-Containing 3 Protein; Pain Threshold; Random Allocation; Rats, Sprague-Dawley; Receptors, Purinergic P2X4; Reproducibility of Results; Signal Transduction; Spine; Streptozocin; Sural Nerve; Time Factors | 2019 |
The effects of dexmedetomidine in increased intestinal permeability after traumatic brain injury: An experimental study.
Topics: Animals; Brain Injuries, Traumatic; Cytokines; Dexmedetomidine; Disease Models, Animal; Inflammation; Intestinal Absorption; Intestinal Mucosa; Rats | 2020 |
Pretreatment with dexmedetomidine alleviates lung injury in a rat model of intestinal ischemia reperfusion.
Topics: Acute Lung Injury; Animals; Antioxidants; Cytokines; Dexmedetomidine; Disease Models, Animal; Heme Oxygenase-1; Lung; Male; Malondialdehyde; NF-E2 Transcription Factor; Oxidative Stress; Peroxidase; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Signal Transduction; Superoxide Dismutase | 2020 |
The Effects of Dexmedetomidine in a Rat Model of Sepsis-Induced Lung Injury are Mediated Through the Adenosine Monophosphate-Activated Protein Kinase (AMPK)/Silent Information Regulator 1 (SIRT1) Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Body Temperature; Cytokines; Dexmedetomidine; Disease Models, Animal; Inflammation Mediators; Lung; Lung Injury; Male; Rats, Sprague-Dawley; Sepsis; Signal Transduction; Sirtuin 1; Survival Analysis | 2020 |
Dexmedetomidine Pretreatment Improves Lipopolysaccharide-induced Iron Homeostasis Disorder in Aged Mice.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Hippocampus; Homeostasis; Inflammation; Iron; Lipopolysaccharides; Male; Maze Learning; Neuroprotective Agents; Oxidative Stress; Reactive Oxygen Species | 2020 |
Dexmedetomidine alleviated neuropathic pain in dorsal root ganglion neurons by inhibition of anaerobic glycolysis activity and enhancement of ROS tolerance.
Topics: Acetylcysteine; Anaerobiosis; Animals; Apoptosis; Cells, Cultured; Dexmedetomidine; Disease Models, Animal; Ganglia, Spinal; Glucose; Glycolysis; Humans; Hydrogen Peroxide; Neuralgia; Neurons; Primary Cell Culture; Rats; Reactive Oxygen Species | 2020 |
TRPV1 Contributes to the Neuroprotective Effect of Dexmedetomidine in Pilocarpine-Induced Status Epilepticus Juvenile Rats.
Topics: Animals; Apoptosis; Calcium; Caspase 3; Dexmedetomidine; Disease Models, Animal; Male; Membrane Potential, Mitochondrial; Neuroprotective Agents; Pilocarpine; Rats; Reactive Oxygen Species; Status Epilepticus; TRPV Cation Channels | 2020 |
Dexmedetomidine postconditioning suppresses myocardial ischemia/reperfusion injury by activating the SIRT1/mTOR axis.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Autophagy; Dexmedetomidine; Disease Models, Animal; Inflammation Mediators; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxidative Stress; Rats, Sprague-Dawley; Signal Transduction; Sirtuin 1; TOR Serine-Threonine Kinases | 2020 |
Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemokines; Dexmedetomidine; Disease Models, Animal; Disease Progression; Hepatic Stellate Cells; Humans; Interleukin-6; Liver Cirrhosis; Liver Neoplasms; Male; Mice, Inbred C57BL; Neoplasm Metastasis; Receptors, Adrenergic, alpha-2; STAT3 Transcription Factor | 2020 |
Dexmedetomidine and Cognitive Dysfunction after Critical Illness: What Can (and Cannot) Be Extrapolated from Rodent Models.
Topics: Analgesics, Non-Narcotic; Animals; Cognitive Dysfunction; Critical Care; Critical Illness; Dexmedetomidine; Disease Models, Animal; Humans; Mice; Rodentia | 2020 |
Dexmedetomidine inhibits pyroptosis by down-regulating miR-29b in myocardial ischemia reperfusion injury in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Cell Line; Dexmedetomidine; Disease Models, Animal; Down-Regulation; Forkhead Box Protein O3; Humans; Male; MicroRNAs; Myocardial Reperfusion Injury; Myocardium; Protective Agents; Pyroptosis; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2020 |
Dexmedetomidine alleviates blunt chest trauma and hemorrhagic shock‑resuscitation‑induced acute lung injury through inhibiting the NLRP3 inflammasome.
Topics: Acute Lung Injury; Animals; Cytokines; Dexmedetomidine; Disease Models, Animal; Gene Expression Regulation; Injections, Intraperitoneal; L-Lactate Dehydrogenase; Male; Malondialdehyde; NLR Family, Pyrin Domain-Containing 3 Protein; Peroxidase; Rats; Resuscitation; Shock, Hemorrhagic; Signal Transduction; Superoxide Dismutase; Thoracic Injuries; Wounds, Nonpenetrating | 2020 |
The Effects of Dexmedetomidine and Ketamine on Oxidative Injuries and Histological Changes Following Blunt Chest Trauma.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Ketamine; Male; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Thoracic Injuries; Wounds, Nonpenetrating | 2020 |
Delayed Adjunctive Treatment of Organophosphate-Induced Status Epilepticus in Rats with Phenobarbital, Memantine, or Dexmedetomidine.
Topics: Animals; Anticonvulsants; Brain; Cell Death; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Electroencephalography; Isoflurophate; Male; Memantine; Neurons; Phenobarbital; Prohibitins; Rats; Rats, Sprague-Dawley; Status Epilepticus; Time-to-Treatment; Treatment Outcome | 2020 |
The Effects of Dexmedetomidine Post-Conditioning on Cardiac and Neurological Outcomes After Cardiac Arrest and Resuscitation in Swine.
Topics: Animals; Brain Diseases; Cardiopulmonary Resuscitation; Dexmedetomidine; Disease Models, Animal; Heart Arrest; Heart Diseases; Male; Random Allocation; Swine; Treatment Outcome | 2021 |
How does intraarticular dexmedetomidine injection effect articular cartilage and synovium? An animal study.
Topics: Analgesics, Non-Narcotic; Animals; Cartilage, Articular; Dexmedetomidine; Disease Models, Animal; Edema; Fibrosis; Inflammation; Injections, Intra-Articular; Male; Pain, Postoperative; Rats; Rats, Sprague-Dawley; Synovial Membrane | 2020 |
Effects of local dexmedetomidine administration on the neurotoxicity of ropivacaine for sciatic nerve block in rats.
Topics: Animals; Apoptosis; Autonomic Nerve Block; Caspase 3; Chemotherapy, Adjuvant; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation; Male; Neurotoxicity Syndromes; Rats; Ropivacaine; Sciatic Nerve | 2020 |
An α
Topics: Adrenergic alpha-2 Receptor Agonists; AMP-Activated Protein Kinases; Animals; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Cardiomegaly; Cells, Cultured; Dexmedetomidine; Disease Models, Animal; Drug Evaluation, Preclinical; Heart Failure; Humans; Male; Membrane Potential, Mitochondrial; Mice; Mitochondria; Myocytes, Cardiac; Primary Cell Culture; Rats; Signal Transduction | 2020 |
Dexmedetomidine alleviates neurobehavioral impairments and myelination deficits following lipopolysaccharide exposure in early postnatal rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Animals, Newborn; Behavior, Animal; Brain Injuries; Dexmedetomidine; Disease Models, Animal; Female; Gliosis; Inflammation; Lipopolysaccharides; Male; Neuroprotective Agents; Pregnancy; Rats; Rats, Sprague-Dawley; STAT3 Transcription Factor | 2020 |
Dexmedetomidine inhibits microglial activation through SNHG14/HMGB1 pathway in spinal cord ischemia-reperfusion injury mice.
Topics: Animals; Behavior, Animal; Dexmedetomidine; Disease Models, Animal; HMGB1 Protein; Locomotion; Mice; Microglia; Reperfusion Injury; RNA, Long Noncoding; Signal Transduction; Spinal Cord Vascular Diseases | 2022 |
Dexmedetomidine inhibits inflammatory response and autophagy through the circLrp1b/miR-27a-3p/Dram2 pathway in a rat model of traumatic brain injury.
Topics: Animals; Anti-Inflammatory Agents; Autophagy; Behavior, Animal; Brain; Brain Injuries, Traumatic; Dexmedetomidine; Disease Models, Animal; Gene Expression Regulation; Inflammation Mediators; Male; MicroRNAs; Rats, Sprague-Dawley; RNA, Circular; Signal Transduction | 2020 |
Dexmedetomidine reduces ventilator-induced lung injury via ERK1/2 pathway activation.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; Bronchoalveolar Lavage Fluid; Cytokines; Dexmedetomidine; Disease Models, Animal; Lung; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; NF-kappa B; Pneumonia; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Ventilator-Induced Lung Injury | 2020 |
Dexmedetomidine attenuates sevoflurane‑induced neurocognitive impairment through α2‑adrenoceptors.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Caspase 3; Cognitive Dysfunction; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Morris Water Maze Test; Random Allocation; Sevoflurane; Superoxide Dismutase; Treatment Outcome; Yohimbine | 2021 |
Dexmedetomidine and Clonidine Attenuate Sevoflurane-Induced Tau Phosphorylation and Cognitive Impairment in Young Mice via α-2 Adrenergic Receptor.
Topics: Adrenergic alpha-2 Receptor Agonists; Age Factors; Animals; Behavior, Animal; Clonidine; Cognition; Cognitive Dysfunction; Dexmedetomidine; Disease Models, Animal; Exploratory Behavior; Female; Hippocampus; Male; Mice, Inbred C57BL; Morris Water Maze Test; Phosphorylation; Receptors, Adrenergic, alpha-2; Sevoflurane; tau Proteins | 2021 |
Dexmedetomidine exerts cardioprotective effect through miR-146a-3p targeting IRAK1 and TRAF6 via inhibition of the NF-κB pathway.
Topics: Animals; Apoptosis; Cell Hypoxia; Cell Line; Dexmedetomidine; Disease Models, Animal; Gene Expression Regulation; Interleukin-1 Receptor-Associated Kinases; Male; MicroRNAs; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; TNF Receptor-Associated Factor 6 | 2021 |
Dexmedetomidine Attenuates Lung Injury in Toxic Shock Rats by Inhibiting Inflammation and Autophagy.
Topics: Animals; Autophagy; Dexmedetomidine; Disease Models, Animal; Hypnotics and Sedatives; Inflammation; Lung Injury; Male; Rats; Rats, Sprague-Dawley; Shock, Septic | 2021 |
Perioperative Dexmedetomidine attenuates brain ischemia reperfusion injury possibly via up-regulation of astrocyte Connexin 43.
Topics: Animals; Astrocytes; Brain Ischemia; Connexin 43; Dexmedetomidine; Disease Models, Animal; Hypnotics and Sedatives; Male; Perioperative Care; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Up-Regulation | 2020 |
Dexmedetomidine-up-regulated microRNA-381 exerts anti-inflammatory effects in rats with cerebral ischaemic injury via the transcriptional factor IRF4.
Topics: Animals; Apoptosis; Brain Ischemia; Dexmedetomidine; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Glucose; Interferon Regulatory Factors; Interleukin-9; Male; MicroRNAs; Neurons; Oxygen; Pyramidal Cells; Rats; RNA Interference; Signal Transduction | 2021 |
Effect of dexmedetomidine and cholinergic anti-inflammatory pathways in myocardial ischemia-reperfusion injury.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Apoptosis; Apoptosis Regulatory Proteins; Cholinergic Agents; Creatine Kinase; Cytokines; Dexmedetomidine; Disease Models, Animal; Inflammation Mediators; L-Lactate Dehydrogenase; Male; Myocardial Reperfusion Injury; Myocardium; Rats, Wistar; Up-Regulation | 2020 |
Neuroprotective Effects Against Cerebral Ischemic Injury Exerted by Dexmedetomidine via the HDAC5/NPAS4/MDM2/PSD-95 Axis.
Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Brain Ischemia; Cell Survival; Dexmedetomidine; Disease Models, Animal; Disks Large Homolog 4 Protein; Hippocampus; Histone Deacetylases; Male; Mice; Neurons; Neuroprotective Agents; Proto-Oncogene Proteins c-mdm2; Signal Transduction | 2021 |
Effect of intra-articular dexmedetomidine on experimental osteoarthritis in rats.
Topics: Animals; Cartilage, Articular; Dexmedetomidine; Disease Models, Animal; Injections, Intra-Articular; Interleukin-6; Male; Osteoarthritis; Rats; Rats, Wistar; Synovial Membrane; Tumor Necrosis Factor-alpha | 2021 |
Upregulated microRNA-381-5p strengthens the effect of dexmedetomidine preconditioning to protect against myocardial ischemia-reperfusion injury in mouse models by inhibiting CHI3L1.
Topics: Animals; Apoptosis; Chitinase-3-Like Protein 1; Dexmedetomidine; Disease Models, Animal; Hypnotics and Sedatives; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Signal Transduction; Up-Regulation | 2021 |
Involvement of GPR30 in protection effect of Dexmedetomidine against myocardial ischemia/reperfusion injury in rat via AKT pathway.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cell Survival; Cells, Cultured; Chromones; Dexmedetomidine; Disease Models, Animal; Drug Synergism; Gene Knockdown Techniques; Male; Morpholines; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Quinolines; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Signal Transduction; Transfection | 2021 |
Dexmedetomidine Inhibits Inflammation to Alleviate Early Neuronal Injury via TLR4/NF-κB Pathway in Rats with Traumatic Brain Injury.
Topics: Animals; Apoptosis; Autophagy; Brain Injuries, Traumatic; Cytokines; Dexmedetomidine; Disease Models, Animal; Inflammation; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; Signal Transduction; Toll-Like Receptor 4 | 2021 |
Dexmedetomidine suppresses the development of abdominal aortic aneurysm by downregulating the mircoRNA‑21/PDCD 4 axis.
Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apoptosis Regulatory Proteins; Dexmedetomidine; Disease Models, Animal; Down-Regulation; Gene Expression Regulation; Genes, Reporter; Humans; Male; MicroRNAs; Rats; Rats, Sprague-Dawley | 2021 |
The Protective Mechanism of Dexmedetomidine in Regulating Atg14L-Beclin1-Vps34 Complex Against Myocardial Ischemia-Reperfusion Injury.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Autophagy; Autophagy-Related Proteins; Beclin-1; Chromones; Class III Phosphatidylinositol 3-Kinases; Dexmedetomidine; Disease Models, Animal; Morpholines; Myocytes, Cardiac; Phosphorylation; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Signal Transduction | 2021 |
Dexmedetomidine attenuates neuronal injury induced by cerebral ischemia‑reperfusion by regulating miR‑199a.
Topics: Animals; Antigens, Nuclear; Beclin-1; Brain Ischemia; Caspase 3; Cerebral Cortex; Dexmedetomidine; Disease Models, Animal; Infarction, Middle Cerebral Artery; Injections; Male; MicroRNAs; Microtubule-Associated Proteins; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Rats, Sprague-Dawley; Reperfusion Injury; RNA-Binding Proteins | 2021 |
Dexmedetomidine post-conditioning attenuates cerebral ischemia following asphyxia cardiac arrest through down-regulation of apoptosis and neuroinflammation in rats.
Topics: Animals; Apoptosis; Asphyxia; Brain Ischemia; Cardiopulmonary Resuscitation; Dexmedetomidine; Disease Models, Animal; Down-Regulation; Heart Arrest; Interleukin-1beta; Male; Neuroinflammatory Diseases; Neuroprotective Agents; NF-kappa B; Rats; Rats, Sprague-Dawley; Time Factors | 2021 |
Dexmedetomidine maintains blood-brain barrier integrity by inhibiting Drp1-related endothelial mitochondrial dysfunction in ischemic stroke.
Topics: Adenylate Kinase; Adrenergic alpha-2 Receptor Antagonists; Animals; Blood-Brain Barrier; Cell Line; Cytokines; Dexmedetomidine; Disease Models, Animal; Dynamins; Endothelial Cells; Glial Fibrillary Acidic Protein; Humans; Indole Alkaloids; Infarction, Middle Cerebral Artery; Ischemic Stroke; Male; Mitochondria; Mitochondrial Dynamics; Neuroprotective Agents; Phosphorylation; Rats, Sprague-Dawley; Zonula Occludens-1 Protein | 2021 |
Dexmedetomidine alleviates early brain injury following traumatic brain injury by inhibiting autophagy and neuroinflammation through the ROS/Nrf2 signaling pathway.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Apoptosis; Autophagy; Beclin-1; Brain; Brain Injuries; Brain Injuries, Traumatic; Cell Survival; Cytokines; Dexmedetomidine; Disease Models, Animal; Female; Male; Mice; Mice, Inbred C57BL; Neuroinflammatory Diseases; Neuroprotective Agents; NF-E2-Related Factor 2; Reactive Oxygen Species; Signal Transduction | 2021 |
Protective effects of dexmedetomidine on cerebral ischemia/reperfusion injury via the microRNA-214/ROCK1/NF-κB axis.
Topics: Animals; Apoptosis; Brain Ischemia; Dexmedetomidine; Disease Models, Animal; Hippocampus; Infarction, Middle Cerebral Artery; Male; MicroRNAs; Neuroprotective Agents; NF-kappa B; Rats; Rats, Sprague-Dawley; Reperfusion Injury; rho-Associated Kinases | 2021 |
Asenapine modulates mood-related behaviors and 5-HT
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenocorticotropic Hormone; Affect; Animals; Antipsychotic Agents; Dexmedetomidine; Dibenzocycloheptenes; Disease Models, Animal; Drug Delivery Systems; Heterocyclic Compounds, 4 or More Rings; Male; Neurons; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin; Septal Nuclei; Serotonin Agents; Sleep Deprivation; Swimming; Synaptic Transmission | 2017 |
Effects of ketamine, dexmedetomidine and propofol anesthesia on emotional memory consolidation in rats: Consequences for the development of post-traumatic stress disorder.
Topics: Animals; Avoidance Learning; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Hypnotics and Sedatives; Inhibition, Psychological; Interpersonal Relations; Ketamine; Male; Memory Disorders; Propofol; Rats; Rats, Sprague-Dawley; Sleep Wake Disorders; Stress Disorders, Post-Traumatic | 2017 |
Local injection to sciatic nerve of dexmedetomidine reduces pain behaviors, SGCs activation, NGF expression and sympathetic sprouting in CCI rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Non-Narcotic; Animals; Chronic Pain; Dexmedetomidine; Disease Models, Animal; Male; Microglia; Nerve Growth Factor; Neuralgia; Neurons; Random Allocation; Rats, Sprague-Dawley; Sciatic Nerve; Spinal Cord Dorsal Horn | 2017 |
Dexmedetomidine alleviates lipopolysaccharide-induced lung injury in Wistar rats.
Topics: Animals; Biomarkers; Cytokines; Dexmedetomidine; Disease Models, Animal; Female; Gene Expression Regulation; Inflammation Mediators; Lipopolysaccharides; Lung Injury; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Wistar; Signal Transduction | 2017 |
Synergistic Interaction Between Dexmedetomidine and Ulinastatin Against Vincristine-Induced Neuropathic Pain in Rats.
Topics: Analgesics, Non-Narcotic; Animals; Dexmedetomidine; Disease Models, Animal; Drug Synergism; Ganglia, Spinal; Glycoproteins; Hyperalgesia; Injections, Intraperitoneal; Injections, Spinal; Interleukin-10; Male; Neuralgia; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Specific Pathogen-Free Organisms; Touch; Trypsin Inhibitors; Vincristine | 2017 |
Alternative technique or mitigating strategy for sevoflurane-induced neurodegeneration: a randomized controlled dose-escalation study of dexmedetomidine in neonatal rats.
Topics: Anesthetics, Inhalation; Animals; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Hypnotics and Sedatives; Neurodegenerative Diseases; Random Allocation; Rats; Rats, Wistar; Sevoflurane | 2017 |
Dexmedetomidine-mediated neuroprotection against sevoflurane-induced neurotoxicity extends to several brain regions in neonatal rats.
Topics: Anesthetics, Inhalation; Animals; Animals, Newborn; Apoptosis; Brain; Dexmedetomidine; Disease Models, Animal; Hypnotics and Sedatives; Neuroprotection; Neurotoxicity Syndromes; Rats; Rats, Wistar; Sevoflurane | 2017 |
Dexmedetomidine Increases the Latency of Thermal Antinociception in Rats.
Topics: Acute Pain; Adrenergic alpha-2 Receptor Agonists; Anesthetics, Local; Animals; Dexmedetomidine; Disease Models, Animal; Drug Therapy, Combination; Epinephrine; Injections; Lidocaine; Male; Rats; Rats, Wistar; Time Factors | 2017 |
Different effects of dexmedetomidine and midazolam on the expression of NR2B and GABAA-α1 following peripheral nerve injury in rats.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Hedgehog Proteins; Hyperalgesia; Male; Midazolam; Neuralgia; Peripheral Nerve Injuries; Rats, Sprague-Dawley; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Spinal Cord Dorsal Horn; Thalamus | 2018 |
Dexmedetomidine and Magnesium Sulfate: A Good Combination Treatment for Acute Lung Injury?
Topics: Acute Lung Injury; Administration, Intravenous; Animals; Anti-Inflammatory Agents; Antioxidants; Dexmedetomidine; Disease Models, Animal; Drug Synergism; Hemodynamics; Humans; Hydrochloric Acid; Lung; Magnesium Sulfate; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Respiration, Artificial; Signal Transduction | 2019 |
The protective effect of dexmedetomidine in a rat ex vivo lung model of ischemia-reperfusion injury.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blotting, Western; CCAAT-Enhancer-Binding Proteins; Dexmedetomidine; Disease Models, Animal; Heat-Shock Proteins; Ischemia; Lung; Male; Malondialdehyde; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Reference Values; Reperfusion Injury; Reproducibility of Results; Superoxide Dismutase; Time Factors; Treatment Outcome | 2018 |
Protective effect of dexmedetomidine against myocardial ischemia-reperfusion injury in rabbits.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Endothelin-1; Heart Rate; Hemodynamics; Male; Myocardial Reperfusion Injury; No-Reflow Phenomenon; Platelet Activating Factor; Rabbits; Random Allocation; Reference Values; Reproducibility of Results; Thromboxane A2; Treatment Outcome | 2018 |
Dexmedetomidine stops benzodiazepine-refractory nerve agent-induced status epilepticus.
Topics: Analysis of Variance; Animals; Anticonvulsants; Atropine; Benzodiazepines; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Electroencephalography; Hypnotics and Sedatives; Male; Nerve Agents; Rats; Rats, Sprague-Dawley; Status Epilepticus; Time Factors | 2018 |
Dexmedetomidine to Help Nerve Regeneration in a Rat Sciatic Nerve Injury Model.
Topics: Analgesics, Non-Narcotic; Animals; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Nerve Regeneration; Rats; Rats, Sprague-Dawley; Recovery of Function; Sciatic Neuropathy; Walking | 2017 |
Evaluation of topical Dexmedetomidine administration in postlaminectomy epidural fibrosis rat model.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Epidural Space; Fibrosis; Laminectomy; Male; Postoperative Complications; Rats; Rats, Wistar; Treatment Outcome | 2018 |
Neuroprotective effect of dexmedetomidine in a murine model of traumatic brain injury.
Topics: Animals; Brain Injuries, Traumatic; Cerebral Cortex; Dexmedetomidine; Disease Models, Animal; Hippocampus; Male; Mice; Neuroprotective Agents | 2018 |
Dexmedetomidine inhibits inflammatory reaction in the hippocampus of septic rats by suppressing NF-κB pathway.
Topics: Animals; Anti-Inflammatory Agents; Dexmedetomidine; Disease Models, Animal; Drug Synergism; Gene Expression Regulation; Hippocampus; Injections, Intraperitoneal; Interleukin-6; Lipopolysaccharides; Neuroprotective Agents; NF-kappa B; Proline; Rats; Rats, Sprague-Dawley; Sepsis; Signal Transduction; Thiocarbamates; Tumor Necrosis Factor-alpha | 2018 |
Reactive Astrogliosis in an Experimental Model of Fibromyalgia: Effect of Dexmedetomidine.
Topics: Animals; Astrocytes; Dentate Gyrus; Dexmedetomidine; Disease Models, Animal; Fibromyalgia; Glial Fibrillary Acidic Protein; Gliosis; Male; Nitric Oxide Synthase Type II; Rats, Wistar | 2018 |
Dexmedetomidine and propofol sedation requirements in an autistic rat model.
Topics: Animals; Animals, Newborn; Autistic Disorder; Dexmedetomidine; Disease Models, Animal; Electroencephalography; Female; Hypnotics and Sedatives; Male; Pregnancy; Propofol; Random Allocation; Rats; Rats, Sprague-Dawley | 2019 |
Dexmedetomidine attenuates cerebral ischemia/reperfusion injury in neonatal rats by inhibiting TLR4 signaling.
Topics: Animals; Brain; Brain Ischemia; CA3 Region, Hippocampal; Cerebral Cortex; Dexmedetomidine; Disease Models, Animal; Hypnotics and Sedatives; Lipopolysaccharides; Neuroprotective Agents; Pilot Projects; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Toll-Like Receptor 4 | 2018 |
Dexmedetomidine protects against lipopolysaccharide-induced sepsis-associated acute kidney injury via an α7 nAChR-dependent pathway.
Topics: Acute Kidney Injury; alpha7 Nicotinic Acetylcholine Receptor; Animals; Anti-Inflammatory Agents; Apoptosis; Apoptosis Regulatory Proteins; Cytoprotection; Dexmedetomidine; Disease Models, Animal; Inflammation Mediators; Kidney Tubules; Lipopolysaccharides; Male; Mice, Inbred C57BL; Sepsis; Signal Transduction; Time Factors | 2018 |
Protective Effect of Dexmedetomidine on Endotoxin-Induced Acute Lung Injury in Rats.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Dexmedetomidine; Disease Models, Animal; Endotoxins; Lipopolysaccharides; Lung; Male; Rats; Rats, Sprague-Dawley | 2018 |
Midazolam and Dexmedetomidine Affect Neuroglioma and Lung Carcinoma Cell Biology In Vitro and In Vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexmedetomidine; Disease Models, Animal; Flow Cytometry; Fluorescent Antibody Technique; Glioma; Humans; Hypnotics and Sedatives; Lung Neoplasms; Mice; Midazolam | 2018 |
Dexmedetomidine alleviates cerebral ischemia-reperfusion injury by inhibiting endoplasmic reticulum stress dependent apoptosis through the PERK-CHOP-Caspase-11 pathway.
Topics: Animals; Apoptosis; Brain; Brain Ischemia; Caspases; Dexmedetomidine; Disease Models, Animal; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glucose; Heat-Shock Proteins; Infarction, Middle Cerebral Artery; Male; Neurons; Neuroprotection; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Signal Transduction; Transcription Factor CHOP | 2018 |
Protective effect of ulinastatin combined with dexmedetomidine on lung injury after cold ischemia-reperfusion in rats.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Cold Ischemia; Cytokines; Cytoprotection; Dexmedetomidine; Disease Models, Animal; Glycoproteins; Inflammation Mediators; Lipid Peroxidation; Liver Transplantation; Lung; Male; Malondialdehyde; Rats, Sprague-Dawley; Reperfusion Injury; Superoxide Dismutase | 2018 |
Administration of Dexmedetomidine inhibited NLRP3 inflammasome and microglial cell activities in hippocampus of traumatic brain injury rats.
Topics: Animals; Brain Injuries, Traumatic; Caspase 1; Dexmedetomidine; Disease Models, Animal; Hippocampus; Humans; Inflammasomes; Microglia; Neurons; NLR Family, Pyrin Domain-Containing 3 Protein; Rats | 2018 |
Dexmedetomidine Ameliorates Acute Stress-Induced Kidney Injury by Attenuating Oxidative Stress and Apoptosis through Inhibition of the ROS/JNK Signaling Pathway.
Topics: Animals; Apoptosis; Dexmedetomidine; Disease Models, Animal; Kidney; Kidney Tubules; Male; MAP Kinase Signaling System; Mitochondria; Norepinephrine; Oxidative Stress; Protective Agents; Rats, Wistar; Reactive Oxygen Species; Stress, Psychological | 2018 |
Dexmedetomidine preserves the endothelial glycocalyx and improves survival in a rat heatstroke model.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Glycocalyx; Heat Stroke; Inflammation; Male; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2018 |
Dexmedetomidine attenuates lipopolysaccharide-induced liver oxidative stress and cell apoptosis in rats by increasing GSK-3β/MKP-1/Nrf2 pathway activity via the α2 adrenergic receptor.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Chemical and Drug Induced Liver Injury; Cytoprotection; Dexmedetomidine; Disease Models, Animal; Dual Specificity Phosphatase 1; Glycogen Synthase Kinase 3 beta; Lipopolysaccharides; Liver; Male; NF-E2-Related Factor 2; Oxidative Stress; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Signal Transduction | 2019 |
Dexmedetomidine alleviates lung ischemia-reperfusion injury in rats by activating PI3K/Akt pathway.
Topics: Acute Lung Injury; Animals; Dexmedetomidine; Disease Models, Animal; Humans; Lung; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Signal Transduction | 2019 |
Dexmedetomidine inhibits astrocyte pyroptosis and subsequently protects the brain in in vitro and in vivo models of sepsis.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Astrocytes; Brain; Cytokines; Dexmedetomidine; Disease Models, Animal; Histones; Humans; Inflammasomes; Lipopolysaccharides; Male; Neuroglia; Neurons; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein; PC12 Cells; Pyroptosis; Rats; Rats, Sprague-Dawley; Sepsis; Tumor Necrosis Factor-alpha | 2019 |
Dexmedetomidine Protects Against Neurological Dysfunction in a Mouse Intracerebral Hemorrhage Model by Inhibiting Mitochondrial Dysfunction-Derived Oxidative Stress.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Behavior, Animal; Brain; Cerebral Hemorrhage; Dexmedetomidine; Disease Models, Animal; Male; Maze Learning; Mice, Inbred C57BL; Mitochondria; Motor Activity; Neuroprotective Agents; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Reactive Oxygen Species; Superoxide Dismutase; Uncoupling Protein 2 | 2019 |
Protective effect of dexmedetomidine against organ dysfunction in a two-hit model of hemorrhage/resuscitation and endotoxemia in rats.
Topics: Animals; Biomarkers; Dexmedetomidine; Disease Models, Animal; Endotoxemia; Hemorrhage; Male; Multiple Organ Failure; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Receptors, Adrenergic, beta-2; Resuscitation; Time Factors | 2019 |
Anticonvulsant and Neuroprotective Effects of Dexmedetomidine on Pilocarpine-Induced Status Epilepticus in Rats Using a Metabolomics Approach.
Topics: Animals; Anticonvulsants; Brain; Chromatography, Liquid; Dexmedetomidine; Disease Models, Animal; Hippocampus; Hypnotics and Sedatives; Metabolomics; Neurons; Neuroprotective Agents; Pilocarpine; Rats; Rats, Sprague-Dawley; Seizures; Status Epilepticus; Tandem Mass Spectrometry | 2019 |
Dexmedetomidine attenuates myocardial ischemia/reperfusion injury through regulating lactate signaling cascade in mice.
Topics: Animals; Caspase 3; Caspase 9; Coronary Vessels; Cytochromes c; Dexmedetomidine; Disease Models, Animal; Humans; Lactic Acid; Male; Mice; Mitochondria; Monocarboxylic Acid Transporters; Myocardial Reperfusion Injury; Myocardium; Oxidative Stress; Signal Transduction; Symporters | 2019 |
Protective effect of dexmedetomidine against diabetic hyperglycemia-exacerbated cerebral ischemia/reperfusion injury: An in vivo and in vitro study.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Apoptosis; Dexmedetomidine; Diabetes Mellitus, Experimental; Disease Models, Animal; Hyperglycemia; In Vitro Techniques; Infarction, Middle Cerebral Artery; Inflammation; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidative Stress; Reactive Oxygen Species; Reperfusion Injury; Signal Transduction | 2019 |
Long non-coding RNA MALAT1 sponges microRNA-429 to regulate apoptosis of hippocampal neurons in hypoxic-ischemic brain damage by regulating WNT1.
Topics: Animals; Apoptosis; Dexmedetomidine; Disease Models, Animal; Hippocampus; Hypoxia-Ischemia, Brain; Mice; Mice, Inbred C57BL; MicroRNAs; Neurons; RNA, Long Noncoding; Wnt1 Protein | 2019 |
Effect of dexmedetomidine on kidney injury in sepsis rats through TLR4/MyD88/NF-κB/iNOS signaling pathway.
Topics: Acute Kidney Injury; Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Humans; Kidney; Lipopolysaccharides; Male; Myeloid Differentiation Factor 88; NF-kappa B; Nitric Oxide Synthase Type II; Rats; Sepsis; Signal Transduction; Specific Pathogen-Free Organisms; Toll-Like Receptor 4 | 2019 |
Dexmedetomidine ameliorates LPS induced acute lung injury via GSK-3β/STAT3-NF-κB signaling pathway in rats.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Dexmedetomidine; Disease Models, Animal; Glycogen Synthase Kinase 3 beta; Humans; Inflammation; Lipopolysaccharides; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; Signal Transduction; STAT3 Transcription Factor | 2019 |
Dexmedetomidine suppresses sevoflurane anesthesia-induced neuroinflammation through activation of the PI3K/Akt/mTOR pathway.
Topics: Anesthetics, Inhalation; Animals; Cerebral Cortex; Chromones; Cytokines; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hippocampus; Hypnotics and Sedatives; Inflammation; Morpholines; Neuroprotective Agents; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Random Allocation; Rats, Sprague-Dawley; Sevoflurane; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Effects of dexmedetomidine on myocardial ischemia-reperfusion injury through PI3K-Akt-mTOR signaling pathway.
Topics: Animals; Apoptosis; Cardiotonic Agents; Creatine Kinase; Dexmedetomidine; Disease Models, Animal; Free Radicals; Humans; Male; Myocardial Reperfusion Injury; Myocardium; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Effects of dexmedetomidine on sepsis-induced liver injury in rats.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Lipopolysaccharides; Liver Diseases; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Random Allocation; Rats; Rats, Sprague-Dawley; Sepsis; Survival Analysis; Treatment Outcome | 2019 |
The effects of dexmedetomidine on secondary acute lung and kidney injuries in the rat model of intra-abdominal sepsis.
Topics: Acute Kidney Injury; Acute Lung Injury; Acute-Phase Proteins; Animals; Apoptosis; Caspase 3; Cecum; Cell Count; Creatinine; Dexmedetomidine; Disease Models, Animal; DNA Fragmentation; Kidney; Lipocalin-2; Lipocalins; Lung; Macrophages, Alveolar; Male; Malondialdehyde; Proto-Oncogene Proteins; Rats; Rats, Wistar; Sepsis | 2013 |
The comparison of neuroprotective effects of intrathecal dexmedetomidine and metilprednisolone in spinal cord injury.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Female; Hemorrhage; Histocytochemistry; Injections, Spinal; Methylprednisolone; Neuroprotective Agents; Rats; Rats, Wistar; Spinal Cord; Spinal Cord Injuries; Statistics, Nonparametric | 2013 |
Dexmedetomidine ameliorates TNBS-induced colitis by inducing immunomodulator effect.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Cells, Cultured; Colitis; Cytokines; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Immune System; Immunomodulation; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Spleen; Th17 Cells; Th2 Cells; Trinitrobenzenesulfonic Acid | 2013 |
Interruption of spinal cord microglial signaling by alpha-2 agonist dexmedetomidine in a murine model of delayed paraplegia.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents; Aorta, Thoracic; Cell Survival; Cells, Cultured; Cytokines; Dexmedetomidine; Disease Models, Animal; Inflammation Mediators; Ligation; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Paraplegia; Receptors, Adrenergic, alpha-2; Signal Transduction; Spinal Cord; Time Factors; Toll-Like Receptor 4 | 2014 |
Dexmedetomidine, an α-2a adrenergic agonist, promotes ischemic tolerance in a murine model of spinal cord ischemia-reperfusion.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Aorta, Thoracic; Brain-Derived Neurotrophic Factor; Constriction; CREB-Binding Protein; Dexmedetomidine; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptors, Adrenergic, alpha-2; Reperfusion Injury; Signal Transduction; Spinal Cord; Spinal Cord Ischemia; Time Factors | 2014 |
Histological and biochemical effects of dexmedetomidine on liver during an inflammatory bowel disease.
Topics: Analgesics, Non-Narcotic; Animals; Biochemical Phenomena; Dexmedetomidine; Disease Models, Animal; Inflammatory Bowel Diseases; Liver; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Oxidative Stress | 2015 |
The role of alpha-2 adrenoceptor subtype in the antiallodynic effect of intraplantar dexmedetomidine in a rat spinal nerve ligation model.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Non-Narcotic; Animals; Axotomy; Dexmedetomidine; Disease Models, Animal; Hyperalgesia; Ligation; Male; Neuralgia; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Spinal Nerves | 2013 |
Dexmedetomidine regulates inflammatory molecules contributing to ventilator-induced lung injury in dogs.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blood Gas Analysis; Dexmedetomidine; Disease Models, Animal; Dogs; Lung; Neutrophils; NF-kappa B; Nitric Oxide Synthase Type II; Organ Size; Peroxidase; Random Allocation; Respiration, Artificial; Tumor Necrosis Factor-alpha; Ventilator-Induced Lung Injury | 2014 |
Pharmacokinetics of dexmedetomidine combined with therapeutic hypothermia in a piglet asphyxia model.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Asphyxia Neonatorum; Dexmedetomidine; Disease Models, Animal; Hypothermia, Induced; Hypoxia-Ischemia, Brain; Male; Metabolic Clearance Rate; Neuroprotective Agents; Nonlinear Dynamics; Sus scrofa; Swine | 2014 |
Effects of dexmedetomidine on P2X4Rs, p38-MAPK and BDNF in spinal microglia in rats with spared nerve injury.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blotting, Western; Brain-Derived Neurotrophic Factor; Dexmedetomidine; Disease Models, Animal; Fluorescent Antibody Technique; Hypnotics and Sedatives; Injections, Intraperitoneal; Male; Microglia; Neuralgia; p38 Mitogen-Activated Protein Kinases; Pain Threshold; Rats, Sprague-Dawley; Receptors, Purinergic P2X4; Sciatic Nerve; Spinal Cord | 2014 |
Dexmedetomidine alleviates anxiety-like behaviors and cognitive impairments in a rat model of post-traumatic stress disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Anxiety Agents; Anxiety; Cognition Disorders; Conditioning, Psychological; Dexmedetomidine; Disease Models, Animal; Electroshock; Fear; Freezing Reaction, Cataleptic; Male; Motor Activity; Nootropic Agents; Random Allocation; Rats, Sprague-Dawley; Spatial Memory; Stress Disorders, Post-Traumatic | 2014 |
Dexmedetomidine provides neuroprotection: impact on ketamine-induced neuroapoptosis in the developing rat brain.
Topics: Analgesics, Non-Narcotic; Analysis of Variance; Anesthetics, Dissociative; Animals; Apoptosis; Brain; Dexmedetomidine; Disease Models, Animal; Female; Ketamine; Male; Maze Learning; Memory; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Sodium Chloride | 2014 |
Effects of short-term propofol and dexmedetomidine on pulmonary morphofunction and biological markers in experimental mild acute lung injury.
Topics: Acute Lung Injury; Animals; Cytokines; Dexmedetomidine; Disease Models, Animal; Endotoxins; Female; Hypnotics and Sedatives; Lipopolysaccharides; Lung; NF-E2 Transcription Factor; Nitric Oxide Synthase; Propofol; Rats; Rats, Wistar; RNA, Messenger; Statistics, Nonparametric; Thiopental | 2014 |
Effect of dexmedetomidine on erythrocyte deformability during ischaemia-reperfusion injury of heart in diabetic rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Diabetes Mellitus, Experimental; Disease Models, Animal; Erythrocyte Deformability; Male; Myocardial Reperfusion Injury; Rats, Wistar | 2014 |
Dexmedetomidine alleviates rat post-ischemia induced allodynia through GRK2 upregulation in superior cervical ganglia.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Forelimb; Functional Laterality; G-Protein-Coupled Receptor Kinase 2; Gene Expression Regulation; Hyperalgesia; Hypnotics and Sedatives; Ischemia; Neurons; Pain Threshold; Rats; Reperfusion Injury; Statistics, Nonparametric; Superior Cervical Ganglion; Time Factors | 2015 |
Dexmedetomidine preconditioning attenuates global cerebral ischemic injury following asphyxial cardiac arrest.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Asphyxia; Brain; Brain Ischemia; Dexmedetomidine; Disease Models, Animal; Heart Arrest; Hypoxia-Inducible Factor 1, alpha Subunit; Ischemic Preconditioning; Neurons; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A | 2016 |
Dexmedetomidine on renal ischemia-reperfusion injury in rats: assessment by means of NGAL and histology.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Kidney Tubules; Lipocalin-2; Lipocalins; Protective Agents; Proto-Oncogene Proteins; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Time Factors; Treatment Outcome | 2015 |
Neuroprotective effect of dexmedetomidine on hyperoxia-induced toxicity in the neonatal rat brain.
Topics: Animals; Animals, Newborn; Apoptosis; Brain Injuries; Dexmedetomidine; Disease Models, Animal; Down-Regulation; Glutathione; Hyperoxia; Interleukin-1beta; Lipid Peroxidation; Male; Malondialdehyde; Neuroprotective Agents; Rats; Rats, Wistar | 2015 |
The effect of dexmedetomidine against oxidative and tubular damage induced by renal ischemia reperfusion in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Kidney; Kidney Tubules; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2015 |
Dexmedetomidine Attenuates Neurotoxicity Induced by Prenatal Propofol Exposure.
Topics: Anesthetics, Intravenous; Animals; Blotting, Western; Brain; Calcium-Binding Proteins; Caspase 3; Dexmedetomidine; Disease Models, Animal; Female; Hypnotics and Sedatives; Microfilament Proteins; Neurotoxicity Syndromes; Pregnancy; Prenatal Exposure Delayed Effects; Propofol; Rats; Rats, Sprague-Dawley | 2016 |
Dexmedetomidine attenuates blood-spinal cord barrier disruption induced by spinal cord ischemia reperfusion injury in rats.
Topics: Angiopoietin-1; Animals; Capillary Permeability; Dexmedetomidine; Disease Models, Animal; Injections, Spinal; Ischemic Preconditioning; Male; Matrix Metalloproteinase 9; Rats; Receptor, TIE-2; Reperfusion Injury; Spinal Cord; Spinal Cord Ischemia | 2015 |
Potential of the ovine brain as a model for anesthesia-induced neuroapoptosis.
Topics: Animals; Apoptosis; Brain; Dexmedetomidine; Disease Models, Animal; Feasibility Studies; Hernias, Diaphragmatic, Congenital; Isoflurane; Sheep, Domestic | 2015 |
Dexmedetomidine prevents post-ischemic LTP via presynaptic and postsynaptic mechanisms.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brain Ischemia; CA1 Region, Hippocampal; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dexmedetomidine; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glucose; Glutamic Acid; Long-Term Potentiation; Miniature Postsynaptic Potentials; Neuroprotective Agents; Norepinephrine; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses; Tissue Culture Techniques | 2015 |
Preclinical efficacy of Dexmedetomidine on spinal cord injury provoked oxidative renal damage.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Apoptosis; Caspase 3; Creatinine; Dexmedetomidine; Disease Models, Animal; Interleukin-6; Kidney; Oxidative Stress; Peroxidase; Postoperative Complications; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries; Tumor Necrosis Factor-alpha | 2015 |
Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Cytokines; Cytoprotection; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Inflammation Mediators; Lipopolysaccharides; Lung; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neutrophil Infiltration; Phosphorylation; Pulmonary Edema; Time Factors; Transcription Factors; Transcription, Genetic | 2015 |
Effects of dexmedetomidine on the protection of hyperoxia-induced lung injury in newborn rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Animals, Newborn; Aquaporin 1; Cytokines; Cytoprotection; Dexmedetomidine; Disease Models, Animal; Hyperoxia; Inflammation Mediators; Lung; Lung Injury; Macrophages; Pneumonia; Pulmonary Edema; Rats, Sprague-Dawley | 2015 |
Protective effects of udenafil citrate, piracetam and dexmedetomidine treatment on testicular torsion/detorsion-induced ischaemia/reperfusion injury in rats.
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Male; Piracetam; Protective Agents; Pyrimidines; Rats; Rats, Wistar; Reperfusion Injury; Spermatic Cord Torsion; Sulfonamides; Treatment Outcome | 2016 |
Activation of α2 adrenoceptor attenuates lipopolysaccharide-induced hepatic injury.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Chemical and Drug Induced Liver Injury; Cytoprotection; Dexmedetomidine; Disease Models, Animal; Interleukin-1beta; Interleukin-6; Lactic Acid; Lipopolysaccharides; Liver; Male; Malondialdehyde; Oxidative Stress; Rats, Sprague-Dawley; Receptors, Adrenergic, beta-2; Sepsis; Superoxide Dismutase; Time Factors; Tumor Necrosis Factor-alpha; Yohimbine | 2015 |
Clinical and Histological Effects of the Intrathecal Administration of a Single Dose of Dexmedetomidine in Rabbits.
Topics: Analgesics, Non-Narcotic; Animals; Dexmedetomidine; Disease Models, Animal; Female; Glial Fibrillary Acidic Protein; Immunohistochemistry; Injections, Spinal; Meninges; Motor Skills; Nociception; Rabbits; Spinal Cord; Subarachnoid Space | 2016 |
Dexmedetomidine post-treatment induces neuroprotection via activation of extracellular signal-regulated kinase in rats with subarachnoid haemorrhage.
Topics: Analgesics, Non-Narcotic; Animals; Blood-Brain Barrier; Blotting, Western; Dexmedetomidine; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Male; Neuroprotection; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Subarachnoid Hemorrhage | 2016 |
Effect of dexmedetomidine and cold stress in a rat model of neuropathic pain: Role of interleukin-6 and tumor necrosis factor-α.
Topics: Animals; Body Weight; Cold-Shock Response; Dexmedetomidine; Disease Models, Animal; Hyperalgesia; Interleukin-6; Male; Neuralgia; Nociception; Pain Threshold; Rats; Rats, Wistar; Reaction Time; Sympathetic Nervous System; Tumor Necrosis Factor-alpha | 2016 |
Curcumin and dexmedetomidine prevents oxidative stress and renal injury in hind limb ischemia/reperfusion injury in a rat model.
Topics: Acute Kidney Injury; Animals; Antioxidants; Curcumin; Dexmedetomidine; Disease Models, Animal; Extremities; Kidney; Kidney Function Tests; Oxidative Stress; Rats; Reperfusion Injury; Treatment Outcome | 2016 |
Attenuation of neuroinflammation by dexmedetomidine is associated with activation of a cholinergic anti-inflammatory pathway in a rat tibial fracture model.
Topics: Aconitine; Adrenergic alpha-2 Receptor Agonists; alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Dexmedetomidine; Disease Models, Animal; Encephalitis; Hippocampus; Interleukin-1beta; Male; Microglia; Neuroprotective Agents; NF-kappa B; Rats; Rats, Sprague-Dawley; Tibial Fractures; Tumor Necrosis Factor-alpha | 2016 |
Effects of dexmedetomidine postconditioning on myocardial ischemia and the role of the PI3K/Akt-dependent signaling pathway in reperfusion injury.
Topics: Animals; bcl-2-Associated X Protein; Biomarkers; Cardiotonic Agents; Caspase 3; Creatine Kinase, MB Form; Dexmedetomidine; Disease Models, Animal; Glycogen Synthase Kinase 3 beta; Ischemic Postconditioning; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Rats; RNA, Messenger; Signal Transduction; Superoxide Dismutase | 2016 |
Dexmedetomidine attenuates repeated propofol exposure-induced hippocampal apoptosis, PI3K/Akt/Gsk-3β signaling disruption, and juvenile cognitive deficits in neonatal rats.
Topics: Analgesics; Animals; Apoptosis; bcl-2-Associated X Protein; Biomarkers; Blood Gas Analysis; Caspase 3; Cognitive Dysfunction; Dexmedetomidine; Disease Models, Animal; Glycogen Synthase Kinase 3 beta; Hippocampus; Male; Phosphatidylinositol 3-Kinases; Propofol; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Rats; Signal Transduction | 2016 |
[Effects of dexmedetomidine on microcirculatory perfusion in rabbits with renal ischemia/reperfusion injury: quantitative evaluation with contrast-enhanced ultrasound].
Topics: Animals; Dexmedetomidine; Disease Models, Animal; Kidney; Kidney Diseases; Microcirculation; Rabbits; Renal Artery; Reperfusion Injury | 2016 |
α2-adrenoreceptor modulated FAK pathway induced by dexmedetomidine attenuates pulmonary microvascular hyper-permeability following kidney injury.
Topics: Actins; Acute Kidney Injury; Acute Lung Injury; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antigens, CD; Cadherins; Capillary Permeability; Cells, Cultured; Dexmedetomidine; Disease Models, Animal; Endothelial Cells; Endothelium; Focal Adhesion Kinase 1; Humans; Imidazoles; Kidney; Lung; Male; Mice; Mice, Inbred C57BL; Phosphorylation; Receptors, Adrenergic, alpha-2; Reperfusion Injury; Signal Transduction | 2016 |
Comparison of histopathological effects of perineural administration of bupivacaine and bupivacaine-dexmedetomidine in rat sciatic nerve.
Topics: Anesthetics, Local; Animals; Bupivacaine; Dexmedetomidine; Disease Models, Animal; Microscopy, Electron, Transmission; Neurotoxicity Syndromes; Rats; Rats, Sprague-Dawley; Sciatic Nerve | 2016 |
Dexmedetomidine protected COPD-induced lung injury by regulating miRNA-146a.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Apoptosis; Dexmedetomidine; Disease Models, Animal; Gene Expression Regulation; Interleukin-1beta; Lung; MicroRNAs; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; Respiratory Function Tests; Tumor Necrosis Factor-alpha | 2016 |
Dexmedetomidine protects against glucocorticoid induced progenitor cell apoptosis in neonatal mouse cerebellum.
Topics: Animals; Animals, Newborn; Apoptosis; Cell Culture Techniques; Cerebellum; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Glucocorticoids; Mice; Mice, Inbred ICR; Neuroprotective Agents; Random Allocation; Respiration; Signal Transduction; Stem Cells | 2017 |
Effect of dexmedetomidine priming on convulsion reaction induced by lidocaine.
Topics: Administration, Topical; Adrenergic alpha-2 Receptor Agonists; Anesthetics, Local; Animals; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Lidocaine; Male; Rabbits; Seizures | 2016 |
Dexmedetomidine may upregulate the expression of caveolin‑1 in lung tissues of rats with sepsis and improve the short‑term outcome.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Blood Gas Analysis; Body Temperature; Caveolin 1; Dexmedetomidine; Disease Models, Animal; Hypnotics and Sedatives; Imidazoles; Lung; Male; Rats; Rats, Sprague-Dawley; Sepsis; Toll-Like Receptor 4; Up-Regulation | 2017 |
Different doses of dexmedetomidine reduce plasma cytokine production, brain oxidative injury, PARP and caspase expression levels but increase liver oxidative toxicity in cerebral ischemia-induced rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Brain; Brain Ischemia; Caspase 1; Cytokines; Dexmedetomidine; Disease Models, Animal; Glutathione; Inflammation Mediators; Liver; Male; Malondialdehyde; Oxidative Stress; Poly (ADP-Ribose) Polymerase-1; Rats, Wistar | 2017 |
Neurodegenerative changes and neuroapoptosis induced by systemic lipopolysaccharide administration are reversed by dexmedetomidine treatment in mice.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Brain; Brain Diseases; Dexmedetomidine; Disease Models, Animal; Interleukin-1beta; Lipopolysaccharides; Male; Malondialdehyde; Mice, Inbred BALB C; Neurodegenerative Diseases; Neuroimmunomodulation; Neurons; Neuroprotective Agents; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Reactive Oxygen Species; Sepsis; Tumor Necrosis Factor-alpha | 2017 |
Global reduction of information exchange during anesthetic-induced unconsciousness.
Topics: Anesthetics, Inhalation; Animals; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Image Processing, Computer-Assisted; Isoflurane; Magnetic Resonance Imaging; Male; Neural Pathways; Oxygen; Rats; Rats, Long-Evans; Reflex; Rest; Unconsciousness | 2017 |
The influence of dexmedetomidine on ischemic rat hippocampus.
Topics: Adrenergic alpha-Agonists; Analysis of Variance; Animals; Catalase; Cytokines; Dexmedetomidine; Disease Models, Animal; Hippocampus; In Situ Nick-End Labeling; Ischemia; Male; Malondialdehyde; Neurons; Nitric Oxide; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2008 |
Dose- and time-related effects of dexmedetomidine on mortality and inflammatory responses to endotoxin-induced shock in rats.
Topics: Adrenergic alpha-Agonists; Animals; Blood Gas Analysis; Blood Pressure; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Rate; Inflammation; Interleukin-6; Male; Random Allocation; Rats; Rats, Wistar; Shock, Septic; Survival Rate; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
Dexmedetomidine and ST-91 analgesia in the formalin model is mediated by alpha2A-adrenoceptors: a mechanism of action distinct from morphine.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Analgesics; Animals; Clonidine; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Formaldehyde; Gene Expression Regulation; Injections, Spinal; Male; Morphine; Pain; Pain Measurement; Posterior Horn Cells; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Neurokinin-1; Substance P | 2008 |
Effects of dexmedetomidine on regulating pulmonary inflammation in a rat model of ventilator-induced lung injury.
Topics: Adrenergic alpha-Agonists; Animals; Carbon Dioxide; Cyclooxygenase 2; Cytokines; Dexmedetomidine; Dinoprostone; Disease Models, Animal; Lung; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Oxygen; Rats; Rats, Sprague-Dawley; Ventilator-Induced Lung Injury | 2008 |
Does dexmedetomidine reduce secondary damage after spinal cord injury? An experimental study.
Topics: Adrenergic alpha-Agonists; Animals; Antioxidants; Apoptosis; Dexmedetomidine; Disease Models, Animal; Disease Progression; Energy Metabolism; Female; Lipid Peroxidation; Male; Nerve Degeneration; Neuroprotective Agents; Oxidative Stress; Paraplegia; Rabbits; Spinal Cord; Spinal Cord Injuries; Treatment Failure | 2009 |
Re: The neuroprotective effect of dexmedetomidine in the hippocampus of rabbits after subarachnoid hemorrhage (Cosar et al. Surg Neurol 2009;71:54-59).
Topics: Adrenergic alpha-Agonists; Animals; Antihypertensive Agents; Dexmedetomidine; Disease Models, Animal; Hippocampus; Humans; Neuroprotective Agents; Rabbits; Reserpine; Subarachnoid Hemorrhage; Vasospasm, Intracranial | 2009 |
The effects of dexmedetomidine dosage on cerebral vasospasm in a rat subarachnoid haemorrhage model.
Topics: Analgesics, Non-Narcotic; Animals; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Pons; Rats; Rats, Wistar; Subarachnoid Hemorrhage; Vasospasm, Intracranial | 2010 |
Protective effects of dexmedetomidine-ketamine combination against ventilator-induced lung injury in endotoxemia rats.
Topics: Animals; Anti-Inflammatory Agents; Dexmedetomidine; Disease Models, Animal; Drug Therapy, Combination; Endotoxemia; Hypnotics and Sedatives; Ketamine; Leukocytes; Lipopolysaccharides; Lung; Lung Injury; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Peroxidase; Rats; Rats, Sprague-Dawley; Ventilators, Mechanical | 2011 |
Evidence for suppression of spinal glial activation by dexmedetomidine in a rat model of monoarthritis.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Arthritis, Experimental; Dexmedetomidine; Disease Models, Animal; Freund's Adjuvant; Hyperalgesia; Injections, Intra-Articular; Male; Neuroglia; Rats; Rats, Sprague-Dawley; Spinal Cord | 2010 |
Antiulcerative effect of dexmedetomidine on indomethacin-induced gastric ulcer in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antioxidants; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Famotidine; Indomethacin; Male; Oxidants; Rats; Rats, Wistar; Stomach Ulcer | 2011 |
Inhibition by dexmedetomidine of the activation of spinal dorsal horn glias and the intracellular ERK signaling pathway induced by nerve injury.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Gliosis; MAP Kinase Signaling System; Neuroglia; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley | 2012 |
Dexmedetomidine prevents remifentanil-induced postoperative hyperalgesia and decreases spinal tyrosine phosphorylation of N-methyl-d-aspartate receptor 2B subunit.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Blotting, Western; Dexmedetomidine; Disease Models, Animal; Hyperalgesia; Male; Pain, Postoperative; Phosphorylation; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Remifentanil; Spinal Cord; Tyrosine | 2012 |
Protective effect of dexmedetomidine in a rat model of α-naphthylthiourea-induced acute lung injury.
Topics: Acute Lung Injury; Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Drug Interactions; Lung; Male; Pleural Effusion; Pneumonia; Pulmonary Edema; Rats; Rats, Wistar; Rodenticides; Thiourea | 2012 |
Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury.
Topics: Analysis of Variance; Animals; Animals, Newborn; Brain Injuries; Cell Count; Dexmedetomidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Flavonoids; Hippocampus; Hypothermia, Induced; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Organ Culture Techniques; Time Factors | 2012 |
Dexmedetomidine prevents alterations of intestinal microcirculation that are induced by surgical stress and pain in a novel rat model.
Topics: Adrenergic alpha-2 Receptor Agonists; Anesthetics, Inhalation; Animals; Blood Flow Velocity; Blood Pressure; Dexmedetomidine; Disease Models, Animal; Heart Rate; Hypertension; Ileum; Infusions, Intravenous; Intestinal Mucosa; Isoflurane; Male; Microcirculation; Microscopy, Video; Muscle, Smooth; Pain, Postoperative; Perfusion Imaging; Rats; Rats, Wistar; Regional Blood Flow; Splanchnic Circulation; Stress, Physiological; Tachycardia; Time Factors; Vasoconstriction | 2012 |
The effects of dexmedetomidine on mesenteric arterial occlusion-associated gut ischemia and reperfusion-induced gut and kidney injury in rabbits.
Topics: Acute Disease; Adrenergic alpha-2 Receptor Agonists; Animals; Antioxidants; Arterial Occlusive Diseases; Dexmedetomidine; Disease Models, Animal; Intestinal Mucosa; Intestines; Kidney; Lipid Peroxidation; Male; Malondialdehyde; Mesenteric Arteries; Oxidants; Peroxidase; Rabbits; Reperfusion Injury; Treatment Outcome | 2012 |
Effect of dexmedetomidine on brain edema and neurological outcomes in surgical brain injury in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blood Glucose; Blood Pressure; Brain; Brain Edema; Brain Injuries; Dexmedetomidine; Disease Models, Animal; Heart Rate; Injections, Intraperitoneal; Male; Motor Activity; Neurologic Examination; Rats; Rats, Sprague-Dawley; Time Factors | 2012 |
Effects of propofol and dexmedetomidine on motor coordination and analgesia: a comparative analysis.
Topics: Analgesics; Animals; Behavior, Animal; Dexmedetomidine; Disease Models, Animal; Hot Temperature; Male; Motor Skills; Pain; Pain Measurement; Pain Threshold; Propofol; Rats; Reaction Time; Time Factors | 2012 |
Dexmedetomidine and clonidine inhibit ventricular tachyarrhythmias in a rabbit model of acquired long QT syndrome.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Animals; Anti-Arrhythmia Agents; Clonidine; Dexmedetomidine; Disease Models, Animal; Heart Conduction System; Humans; Long QT Syndrome; Methoxamine; Pyrimidinones; Rabbits; Tachycardia | 2012 |
Use of dexmedetomidine to prevent pulmonary injury after pneumoperitoneum in ventilated rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Dexmedetomidine; Disease Models, Animal; Female; Lung Injury; Pneumoperitoneum, Artificial; Rats; Rats, Sprague-Dawley; Respiration, Artificial | 2012 |
Analgesic effects of dexmedetomidine in vincristine-evoked painful neuropathic rats.
Topics: Analgesics; Animals; Behavior, Animal; Dexmedetomidine; Disease Models, Animal; Hyperalgesia; Injections, Intraperitoneal; Male; Pain Threshold; Rats; Rats, Sprague-Dawley; Vincristine | 2012 |
Protective effects of dexmedetomidine on blunt chest trauma-induced pulmonary contusion in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Bronchoalveolar Lavage Fluid; Contusions; Cytokines; Dexmedetomidine; Disease Models, Animal; Leukocyte Count; Lung; Lung Injury; Male; Microscopy, Electron, Transmission; Neutrophils; NF-kappa B; Rats; Rats, Sprague-Dawley; Thoracic Injuries; Wounds, Nonpenetrating | 2013 |
Central dexmedetomidine attenuates cardiac dysfunction in a rodent model of intracranial hypertension.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Catecholamines; Dexmedetomidine; Disease Models, Animal; Electrocardiography; Heart Diseases; Heart Function Tests; Heart Rate; Hemodynamics; Intracranial Hypertension; Male; Malondialdehyde; Norepinephrine; Rats; Rats, Sprague-Dawley; Time Factors; Ventricular Function, Left | 2004 |
The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts.
Topics: Adrenergic alpha-Agonists; Animals; Coronary Circulation; Dexmedetomidine; Disease Models, Animal; Heart Arrest; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Sprague-Dawley; Treatment Outcome; Ventricular Function, Left | 2007 |
The central hypotensive effect induced by alpha 2-adrenergic receptor stimulation is dependent on endothelial nitric oxide synthase.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Brain; Dexmedetomidine; Disease Models, Animal; Mice; Mice, Knockout; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Receptors, Adrenergic, alpha-2 | 2008 |